Novel biomarkers in glomerular disease

Advances in Chronic Kidney Disease

Volumn 21, Issue 2, 2014, Pages 205-216

  Caliskan, Yasar ^a,b   Kiryluk, Krzysztof ^a,b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

Focal segmental glomerulosclerosis; Glomerular disease; Immunoglobulin a nephropathy; Membranoproliferative glomerulonephritis; Membranous nephropathy

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4D; COMPLEMENT COMPONENT C5B; COMPLEMENT COMPONENT C9; HEMOGLOBIN; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DQA1 ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MANNOSE BINDING LECTIN; MICRORNA; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ALBUMIN BLOOD LEVEL; ANTIGEN ANTIBODY COMPLEX; CHROMOSOME 22Q; CHROMOSOME 6P; COMPLEMENT BLOOD LEVEL; DISEASE ACTIVITY; DISEASE SEVERITY; END STAGE RENAL DISEASE; FOCAL GLOMERULOSCLEROSIS; GENETIC MARKER; GENETIC RISK; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FUNCTION; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; PODOCYTE; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; URINALYSIS; URINE LEVEL;

FOCAL SEGMENTAL GLOMERULOSCLEROSIS; GLOMERULAR DISEASE; IMMUNOGLOBULIN A NEPHROPATHY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS NEPHROPATHY;

BIOLOGICAL MARKERS; GENETIC MARKERS; GLOMERULONEPHRITIS; GLOMERULONEPHRITIS, IGA; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY;

EID: 84896829987     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2013.12.002     Document Type: Review

References (129)

1. D'Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 2004, 24:179-196.
2. D'Amico G., Minetti L., Ponticelli G. Prognostic indicators in idiopathic IgA mesangial nephropathy. Q J Med 1986, 59:363-378.
3. Alamartine E., Sabatier J.C., Guerin C. Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses. Am J Kidney Dis 1991, 18:12-19.
4. Suzuki H., Kiryluk K., Novak J., et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol 2011, 22(10):1795-1803.
5. Kiryluk K., Novak J., Gharavi A.G. Pathogenesis of immunoglobulin A nephropathy: recent insight from genetic studies. Annu Rev Med 2013, 64:339-356.
6. Wyatt R.J., Julian B.A. IgA nephropathy. N Engl J Med 2013, 368(25):2402-2414.
7. Mestecky J., Raska M., Julian B.A., et al. IgA nephropathy: molecular mechanisms of the disease. Annu Rev Pathol 2013, 8:217-240.
8. Radford M.G., Donadio J.V., Bergstralh E.J., Grande J.P. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 1997, 8(2):199-207.
9. Li P.K., Ho K.K., Szeto C.C., Yu L., Lai F.M. Prognostic indicators of IgA nephropathy in the Chinese-clinical and pathological perspectives. Nephrol Dial Transplant 2002, 17(1):64-69.
10. Lv J., Zhang H., Zhou Y., Li G., Zou W., Wang H. Natural history of immunoglobulin A nephropathy and predictive factors of prognosis: a long-term follow up of 204 cases in China. Nephrology (Carlton) 2008, 13(3):242-246.
11. Goto M., Wakai K., Kawamura T., Ando M., Endoh M., Tomino Y. A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study. Nephrol Dial Transplant 2009, 24(10):3068-3074.
12. Berthoux F., Mohey H., Laurent B., Mariat C., Afiani A., Thibaudin L. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol 2011, 22(4):752-761.
13. Donadio J.V., Bergstralh E.J., Grande J.P., Rademcher D.M. Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy. Nephrol Dial Transplant 2002, 17(7):1197-1203.
14. Reich H.N., Troyanov S., Scholey J.W., Cattran D.C. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 2007, 18(12):3177-3183.
15. Kaartinen K., Syrjanen J., Porsti I., et al. Inflammatory markers and the progression of IgA glomerulonephritis. Nephrol Dial Transplant 2008, 23(4):1285-1290.
16. Xie j, Kiryluk K., Wang W., et al. Predicting progression of IgA Nephropathy: new clinical progression risk score. PLoS One 2012, 7(6):e38904.
17. Roberts I.S., Cook H.T., et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009, 76(5):546-556. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society.
18. Lv J., Shi S., Xu D., et al. Evaluation of the Oxford Classification of IgA Nephropathy: a systematic review and meta-analysis. Am J Kidney Dis 2013, 62(5):891-899.
19. Roberts I.S. Oxford classification of immunoglobulin A nephropathy: an update. Curr Opin Nephrol Hypertens 2013, 22(3):281-286.
20. Roos A., Rastaldi M., Calvaresi N., et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 2006, 17:1724-1734.
21. Espinosa M., Ortega R., Gómez-Carrasco J., et al. Mesangial C4d deposition: a new prognostic factor in IgA nephropathy. Nephrol Dial Transplant 2009, 24(3):886-891.
22. Novak J., Renfrow M., Gharavi A., Julian B. Pathogenesis of immunoglobulin A nephropathy. Curr Opin Nephrol Hypertens 2013, 22(3):287-294.
23. Moldoveanu Z., Wyatt R., Lee J., et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int 2007, 71(11):1148-1154.
24. Suzuki H., Fan R., Zhang Z., et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 2009, 119:1668-1677.
25. Zhao N., Hou P., Lv J., et al. The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int 2012, 82(7):790-796.
26. Gharavi A., Kiryluk K., Choi M., et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 2011, 43:321-327.
27. Kiryluk K., Li Y., Sanna-Cherchi S., et al. Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet 2012, 8(6):e1002765.
28. Berthoux F., Suzuki H., Thibaudin L., et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 2012, 23(9):1579-1587.
29. Matousovic K., Novak J., Tomana M., Kulhavy R., Julian B., Mestecky J. IgA1-containing immune complexes in the urine of IgA nephropathy patients. Nephrol Dial Transplant 2006, 21:2478-2484.
30. Onda K., Ohsawa I., Ohi H., et al. Excretion of complement proteins and its activation marker C5b-9 in IgA nephropathy in relation to renal function. BMC Nephrol 2011, 12:64.
31. Liu L., Jiang Y., Wang L., Liu N. Urinary mannose-binding lectin is a biomarker for predicting the progression of immunoglobulin (Ig)A nephropathy. Clin Exp Immunol 2012, 169:148-155.
32. Julian B.A., Suzuki H., Suzuki Y., Tomino Y., Spasovski G., Novak J. Sources of urinary proteins and their analysis by urinary proteomics for the detection of biomarkers of disease. Proteomics Clin Appl 2009, 3(9):1029-1043.
33. Julian B., Wittke S., Novak J., et al. Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases. Electrophoresis 2007, 8:4469-4483.
34. Santucci L., Candiano G., Bruschi M., et al. Urinary proteome in a snapshot: normal urine and glomerulonephritis. J Nephrol 2013, 26(4):610-616.
35. Wang G., Kwan B., Lai F., Chow K., Li P., Szeto C. Expression of microRNAs in the urinary sediment of patients with IgA nephropathy. Dis Markers 2010, 28:79-86.
36. Wang G., Kwan B., Lai F., et al. Intrarenal expression of microRNAs in patients with IgA nephropathy. Lab Invest 2010, 90:98-103.
37. Wang G., Kwan B., Lai F., Chow K., Li P., Szeto C. Urinary miR-21, miR-29, and miR-93: novel biomarkers of fibrosis. Am J Nephrol 2012, 36(5):412-418.
38. Kiryluk K., Julian B.A., Wyatt R.J., et al. Genetic studies of IgA nephropathy: past, present, and future. Pediatr Nephrol 2010, 25(11):2257-2268.
39. Yu X.Q., Li M., Zhang H., et al. A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy. Nat Genet 2011, 44(2):178-182.
40. Kerjaschki D. Pathomechanisms and molecular basis of membranous glomerulopathy. Lancet 2004, 364:1194-1196.
41. Cattran D. Management of membranous nephropathy: when and what for treatment. J Am Soc Nephrol 2005, 16(5):1188-1194.
42. Pei Y., Cattran D., Greenwood C. Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int 1992, 42(4):960-966.
43. Cattran D., Pei Y., Greenwood C., Ponticelli C., Passerini P., Honkanen E. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int 1997, 51:901-907.
44. van den Brand J.A., Hofstra J.M., Wetzels J.F. Prognostic value of risk score and urinary markers in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2012, 7(8):1242-1248.
45. Sprangers B., Bomback A.S., Cohen S.D., et al. Idiopathic membranous nephropathy: clinical and histologic prognostic features and treatment patterns over time at a tertiary referral center. Am J Nephrol 2012, 36(1):78-89.
46. Badid C., Desmoulière A., McGregor B., et al. Interstitial alpha-smooth muscle actin: a prognostic marker in membranous nephropathy. Clin Nephrol 1999, 52(4):210-217.
47. Yoshimoto K., Wada T., Furuichi K., Sakai N., Iwata Y., Yokoyama H. CD68 and MCP-1/CCR2 expression of initial biopsies reflect the outcomes of membranous nephropathy. Nephron Clin Pract 2004, 98(1):c25-c34.
48. Espinosa-Hernández M., Ortega-Salas R., López-Andreu M., et al. C4d as a diagnostic tool in membranous nephropathy. Nefrologia 2012, 32:295-299.
49. Debiec H., Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med 2011, 364:689-690.
50. Beck L., Bonegio R., Lambeau G., et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009, 361:11-21.
51. Qin W., Beck L.J., Zeng C., et al. Antiphospholipase A2 receptor antibody in membranous nephropathy. Am Soc Nephrol 2011, 22:1137-1143.
52. Hofstra J., Beck L.J., Beck D., Wetzels J., Salant D. Antiphospholipase A receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2011, 6:1286-1291.
53. Debiec H., Martin L., Jouanneau C., et al. Autoantibodies specific for the phospholipase A2 receptor in recurrent and de novo membranous nephropathy. Am J Transplant 2011, 11:2144-2152.
54. Beck L.J., Fervenza F., Beck D., et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011, 22:1543-1550.
55. Hoxha E., Harendza S., Zahner G., et al. An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant 2011, 26:2526-2532.
56. Schönermarck U., Eichhorn P., Sitter T., et al. Performance of anti-phospholipase A2-receptor antibody testing for membranous nephropathy in routine clinical practice. J Am Soc Nephrol 2011, (22):775A. [abstract].
57. Glassock R. Human idiopathic membranous nephropathy-a mystery solved?. N Engl J Med 2009, 361(1):81-83.
58. Knehtl M., Debiec H., Kamgang P., et al. A case of phospholipase A receptor-positive membranous nephropathy preceding sarcoid-associated granulomatous tubulointerstitial nephritis. Am J Kidney Dis 2011, 57(1):140-143.
59. Kon S., Coupes B., Short C., et al. Urinary C5b-9 excretion and clinical course in idiopathic human membranous nephropathy. Kidney Int 1995, 48:1953-1958.
60. Honkanen E., Teppo A., Tornroth T., Groop P., Gronhagen-Riska C. Urinary transforming growth factor-beta 1 in membranous glomerulonephritis. Nephrol Dial Transplant 1997, 12:2562-2568.
61. Bazzi C., Petrini C., Rizza V., et al. Urinary N-acetyl-beta-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis. Nephrol Dial Transplant 2002, 17:1890-1896.
62. Reichert L., Koene R., Wetzels J. Urinary excretion of beta 2-microglobulin predicts renal outcome in patients with idiopathic membranous nephropathy. J Am Soc Nephrol 1995, 6:1666-1669.
63. Reichert L., Koene R., Wetzels J. Urinary IgG excretion as a prognostic factor in idiopathic membranous nephropathy. Clin Nephrol 1997, 48:79-84.
64. Branten A., du Buf-Vereijken P., Klasen I., et al. Urinary excretion of beta2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study. J Am Soc Nephrol 2005, 16:169-174.
65. van den Brand J., Hofstra J., Wetzels J. Low-molecular weight proteins as prognostic markers in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2011, 6:2846-2853.
66. Hofstra J., Deegens J., Steenbergen E., Wetzels J. Urinary excretion of fatty acid-binding proteins in idiopathic membranous nephropathy. Nephrol Dial Transplant 2008, 23(10):3160-3165.
67. Stanescu H., Arcos-Burgos M., Medlar A., et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 2011, 364(7):616-626.
68. Lv J., Hou W., Zhou X., et al. Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy. J Am Soc Nephrol 2013, 24:1323-1329.
69. Benchimol C. Focal segmental glomerulosclerosis: pathogenesis and treatment. Curr Opin Pediatr 2003, 15:171-180.
70. Barisoni L., Schnaper H., Kopp J. Advances in the biology and genetics of the podocytopathies: implications for diagnosis and therapy. Arch Pathol Lab Med 2009, 133:201-216.
71. Santín S., Bullich G., Tazón-Vega B., et al. Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 2001, 6:1139-1148.
72. Meyrier A. Management of Idiopathic Nephrotic Syndrome in Adults: Minimal Change Disease and Focal Segmental Glomerulosclerosis 2009, Wiley-Blackwell, Oxford, UK. 4th ed.
73. Cameron J.S., Turner D.R., Ogg C.S., et al. The long-term prognosis of patients with focal segmental glomerulosclerosis. Clin Nephrol 1978, 10:213-218.
74. Cattran D.C., Rao P. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 1998, 32:72-79.
75. Chitalia V.C., Wells J.E., Robson R.A., et al. Predicting renal survival in primary focal glomerulosclerosis from the time of presentation. Kidney Int 1999, 56:2236-2242.
76. Wehrmann M., Bohle A., Held H., et al. Long-term prognosis of focal sclerosing glomerulonephritis. An analysis of 250 cases with particular regard to tubulointerstitial changes. Clin Nephrol 1990, 33:115-122.
77. Troyanov S., Wall C.A., Miller J.A., et al. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol 2005, 16:1061-1068.
78. Rydel J.J., Korbet S.M., Borok R.Z., et al. Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am J Kidney Dis 1995, 25:534-542.
79. Caridi G., Gigante M., Ravani P., et al. Clinical features and long-term outcome of nephrotic syndrome associated with heterozygous NPHS1 and NPHS2 mutations. Clin J Am Soc Nephrol 2009, 4:1065-1072.
80. D'Agati V., Kaskel F., Falk R. Focal segmental glomerulosclerosis. N Engl J Med 2011, 365(25):2398-2411.
81. Stokes M., Markowitz G., Lin J., Valeri A., D'Agati V. Glomerular tip lesion: a distinct entity within the minimal change disease/focal segmental glomerulosclerosis spectrum. Kidney Int 2004, 65(5):1690-1702.
82. Wei C., El H.S., Li J., et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011, 17:952-960.
83. Garin E., Diaz L., Mu W., et al. Urinary CD80 excretion increases in idiopathic minimal-change disease. J Am Soc Nephrol 2009, 20:260-266.
84. Yu C.C., Fornoni A., Weins A., et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 2013, 369(25):2416-2423.
85. Regele H.M., Fillipovic E., Langer B., et al. Glomerular expression of dystroglycans is reduced in minimal change nephrosis but not in focal segmental glomerulosclerosis. J Am Soc Nephrol 2000, 11:403-412.
86. Giannico G., Yang H., Neilson E., Fogo A. Dystroglycan in the diagnosis of FSGS. Clin J Am Soc Nephrol 2009, 4(11):1747-1753.
87. Hickson L., Gera M., Amer H., et al. Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation 2009, 87:1232-1239.
88. Artero M.L., Sharma R., Savin V.J., Vincenti F. Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis 1994, 23(4):574-581.
89. Haas M., Godfrin Y., Oberbauer R., et al. Plasma immunadsorption treatment in patients with primary focal and segmental glomerulosclerosis. Nephrol Dial Transplant 1998, 13:2013-2016.
90. Kemper M., Wolf G., Müller-Wiefel D. Transmission of glomerular permeability factor from a mother to her child. N Engl J Med 2001, 344:386-387.
91. McCarthy E., Sharma M., Savin V. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2010, 5:2115-2121.
92. Sharma M., Sharma R., McCarthy E., Savin V. "The FSGS factor": enrichment and invivo effect of activity from focal segmental glomerulosclerosis plasma. J Am Soc Nephrol 1999, 10:552-561.
93. Wei C., Trachtman H., Li J., et al. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 2012, 23(12):2051-2059.
94. Sier C., Stephens R., Bizik J., et al. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 1998, 58:1843-1849.
95. Sidenius N., Sier C., Ullum H., et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 2000, 96:4091-4095.
96. Wei C., Möller C., Altintas M., et al. Modification of kidney barrier function by the urokinase receptor. Nat Med 2008, 14:55-63.
97. Kemper M.J., Wei C., Reiser J. Transmission of glomerular permeability factor soluble urokinase plasminogen activator receptor (suPAR) from a mother to child. Am J Kidney Dis 2013, 61(2):352.
98. Huang J., Liu G., Zhang Y.M., et al. Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis. Kidney Int 2013, 84(2):366-372.
99. Alachkar N., Wei C., Arend L.J., et al. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy. Transplantation 2013, 96(7):649-656.
100. Franco Palacios C.R., Lieske J.C., Wadei H.M., et al. Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation 2013, 96(4):394-399.
101. Maas R.J., Deegens J.K., Wetzels J.F. Serum suPAR in patients with FSGS: trash or treasure?. Pediatr Nephrol 2013, 28(7):1041-1048.
102. Trachtman H., Wei C., Reiser J. Circulating factor in FSGS: a black sheep in the suPAR family?. Pediatr Nephrol 2013, 28(7):1151-1152.
103. Reiser J., Wei C., Tumlin J. Soluble urokinase receptor and focal segmental glomerulosclerosis. Curr Opin Nephrol Hypertens 2012, 21(4):428-432.
104. Brown E.J., Schlondorff J.S., Becker D.J., et al. Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis. Nat Genet 2010, 42(1):72-76.
105. Barua M., Brown E., Charoonratana V., Genovese G., Sun H., Pollak M. Mutations in the INF2 gene account for a significant proportion of familial but not sporadic focal and segmental glomerulosclerosis. Kidney Int 2013, 83(2):316-322.
106. Genovese G., Friedman D., Ross M., et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010, 13(5993):841-845.
107. Sethi S., Nester C., Smith R. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int 2012, 81(5):434-441.
108. Bomback A., Appel G. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat Rev Nephrol 2012, 8(11):634-642.
109. Fakhouri F., Fremeaux-Bacchi V., Noel L., Cook H., Pickering M. C3 glomerulopathy: a new classification. Nat Rev Nephrol 2010, 6:494-499.
110. Servais A., Noël L., Roumenina L., et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012, 82:454-464.
111. Sethi S., Fervenza F.C., Zhang Y., et al. C3 glomerulonephritis: clinicopathologic findings, complement abnormalities, glomerular proteomic profile, treatment and follow-up. Kidney Int 2012, 82:465-473.
112. Sethi S., Gamez J., Vrana J., et al. Glomeruli of dense deposit disease contain components of the alternative and terminal complement pathway. Kidney Int 2009, 75:952-960.
113. Onuma T., Laffel L., Angelico M., Krolewski A. Apolipoprotein E genotypes and risk of diabetic nephropathy. J Am Soc Nephrol 1996, 7:1075-1078.
114. Araki S., Moczulski D.K., Hanna L., Scott L.J., Warram J.H., Krolewski A.S. ApoE polymorphisms and the development of diabetic nephropathy in type 1 diabetes: results of case-control and family-based studies. Diabetes 2000, 49:2190-2195.
115. Sethi S., Fervenza F. Membranoproliferative glomerulonephritis-a new look at an old entity. N Engl J Med 2012, 366(12):1119-1131.
116. Zhang Y., Meyer N., Wang K., et al. Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol 2012, 7:265-274.
117. Ruley E., Forristal J., Davis N., Andres C., West C. Hypocomplementemia of membranoproliferative nephritis. Dependence of the nephritic factor reaction on properdin factor B. J Clin Invest 1973, 52:896-904.
118. Vallota E., Götze O., Spiegelberg H., Forristal J., West C., Müller-Eberhard H. A serum factor in chronic hypocomplementemic nephritis distinct from immunoglobulins and activating the alternate pathway of complement. J Exp Med 1974, 139:1249-1261.
119. West C. Nephritic factors predispose to chronic glomerulonephritis. Am J Kidney Dis 1994, 24:956-963.
120. West C., Witte D., McAdams A. Composition of nephritic factor-generated glomerular deposits in membranoproliferative glomerulonephritis type 2. Am J Kidney Dis 2001, 37:1120-1130.
121. Gewurz A., Imherr S., Strauss S., Gewurz H., Mold C. C3 nephritic factor and hypocomplementaemia in a clinically healthy individual. Clin Exp Immunol 1983, 54:253-258.
122. Sissons J., West R., Fallows J., et al. The complement abnormalities of lipodystrophy. N Engl J Med 1976, 294:461-465.
123. Licht C., Heinen S., Józsi M., et al. Deletion of Lys224 in regulatory domain 4 of factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int 2006, 70:42-50.
124. Ruf R.G., Lichtenberger A., Karle S.M., et al. Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 2004, 15:722-732.
125. Sethi S., Fervenza F., Zhang Y., et al. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol 2011, 6:1009-1017.
126. Pickering M., Cook H. Complement and glomerular disease: new insights. Curr Opin Nephrol Hypertens 2011, 20:271-277.
127. Chen Q., Müller D., Rudolph B., et al. Combined C3b and factor B autoantibodies and MPGN type II. N Engl J Med 2011, 365:2340-2342.
128. Habbig S., Mihatsch M., Heinen S., et al. C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int 2009, 75:1230-1234.
129. Gadegbeku C.A., Gipson D.S., Holzman L.B., et al. Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int 2013, 83(4):749-756.